Last reviewed · How we verify
Magnesium Sulfate low dose
Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility.
Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility. Used for Seizure prophylaxis in preeclampsia/eclampsia, Hypertensive emergency management, Neuroprotection in acute neurological conditions.
At a glance
| Generic name | Magnesium Sulfate low dose |
|---|---|
| Also known as | Magnesium Sulfate |
| Sponsor | University of Monastir |
| Drug class | Electrolyte supplement / anticonvulsant |
| Target | NMDA receptor, voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology, Obstetrics, Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Magnesium sulfate blocks calcium influx into cells and antagonizes N-methyl-D-aspartate (NMDA) receptors, leading to reduced neuronal excitability and vasodilation. At low doses, it is used primarily for seizure prophylaxis and management of hypertensive emergencies by stabilizing cell membranes and reducing neuromuscular transmission.
Approved indications
- Seizure prophylaxis in preeclampsia/eclampsia
- Hypertensive emergency management
- Neuroprotection in acute neurological conditions
Common side effects
- Flushing
- Hypotension
- Hypermagnesemia
- Loss of deep tendon reflexes
- Respiratory depression
Key clinical trials
- Magnesium Sulfate Infusion on Postoperative Pain in Lumbar Surgery (NA)
- Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial (NA)
- COMPARISON OF OPIOID-FREE AND OPIOID-BASED ANESTHESIA TECHNIQUES ON qNOX INDEX IN ABDOMINAL SURGERY UNDER GENERAL ANESTHESIA (NA)
- Cleansing Options in Out-Patient Setting to Improve Tolerance (COOP SIT) Trial (PHASE4)
- Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment (PHASE4)
- The Effect of Low Doses of Prednisone on the Prolongation of Pregnancy in Threatened Preterm Birth (PHASE2, PHASE3)
- ESKETamine for FIBromyalgia Treatment (NA)
- Low Dose Magnesium Sulphate (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Magnesium Sulfate low dose CI brief — competitive landscape report
- Magnesium Sulfate low dose updates RSS · CI watch RSS
- University of Monastir portfolio CI